암 모노클로널 항체 제휴 및 라이선싱 계약(2016-2026년)

The definitive benchmark for cancer monoclonal antibody dealmaking

Cancer monoclonal antibody partnering is driven by targeted biologic therapies, with deal structures reflecting the continued evolution of antibody-based approaches across oncology indications.

This report provides a comprehensive and structured analysis of 650+ cancer monoclonal antibody collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how monoclonal antibody deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by development stage, antibody type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a highly competitive and innovation-driven oncology landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within monoclonal antibody partnerships, particularly in areas involving differentiated biologics and targeted treatment strategies.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark oncology biologics transactions
• Prepare for negotiations with well-defined market context
• Evaluate licensing and co-development opportunities
• Support internal strategy with robust, defensible data
• What's included
• 650+ cancer monoclonal antibody collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and antibody type)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for cancer monoclonal antibody dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how monoclonal antibody partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer monoclonal antibody dealmaking

• 2.1. Introduction
• 2.2. Cancer monoclonal antibody deals over the years
• 2.3. Most active cancer monoclonal antibody dealmakers
• 2.4. Cancer monoclonal antibody deals by deal type
• 2.5. Cancer monoclonal antibody deals by therapy area
• 2.6. Cancer monoclonal antibody deals by industry sector
• 2.7. Deal terms for cancer monoclonal antibody deals
  • 2.7.1 Cancer monoclonal antibody deals headline values
  • 2.7.2 Cancer monoclonal antibody deal upfront payments
  • 2.7.3 Cancer monoclonal antibody deal milestone payments
  • 2.7.4 Cancer monoclonal antibody royalty rates

Chapter 3 - Leading cancer monoclonal antibody deals

• 3.1. Introduction
• 3.2. Top cancer monoclonal antibody deals by value

Chapter 4 - Most active cancer monoclonal antibody dealmakers

• 4.1. Introduction
• 4.2. Most active cancer monoclonal antibody dealmakers
• 4.3. Most active cancer monoclonal antibody deals company profiles

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

• Deal directory
• Deal directory - Cancer monoclonal antibody deals by company A-Z
• Deal directory - Cancer monoclonal antibody deals by deal type
• Deal directory - Cancer monoclonal antibody deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cancer monoclonal antibody deals since 2016
• Figure 2: Active cancer monoclonal antibody dealmaking activity since 2016
• Figure 3: Cancer monoclonal antibody deals by deal type since 2016
• Figure 4: Cancer monoclonal antibody deals by therapy area since 2016
• Figure 5: Cancer monoclonal antibody deals by industry sector since 2016
• Figure 6: Cancer monoclonal antibody deals with a headline value
• Figure 7: Cancer monoclonal antibody deals with an upfront value
• Figure 8: Cancer monoclonal antibody deals with a milestone value
• Figure 9: Cancer monoclonal antibody deals with a royalty rate value
• Figure 10: Top cancer monoclonal antibody deals by value since 2016
• Figure 11: Most active cancer monoclonal antibody dealmakers since 2016
• Figure 12: Cancer monoclonal antibody deals by technology type since 2016